BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 38711220)

  • 1. Activation of KIT modulates the function of tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) in mast cells.
    Förster A; Grotha SP; Seeger JM; Rabenhorst A; Gehring M; Raap U; Létard S; Dubreuil P; Kashkar H; Walczak H; Roers A; Hartmann K
    Allergy; 2015 Jul; 70(7):764-74. PubMed ID: 25833810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autocrine/Paracrine Loop Between SCF
    Annese T; Tamma R; Bozza M; Zito A; Ribatti D
    Front Immunol; 2022; 13():794974. PubMed ID: 35140718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Stem Cell Factor in Feline Mast Cell Tumour.
    Sakurai M; Iwasa R; Sakai Y; Chambers JK; Uchida K; Morimoto M
    J Comp Pathol; 2018 Aug; 163():6-9. PubMed ID: 30213375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical localisation of stem cell factor (SCF) with comparison of its receptor c-Kit proto-oncogene product (c-KIT) in melanocytic tumours.
    Takahashi H; Saitoh K; Kishi H; Parsons PG
    Virchows Arch; 1995; 427(3):283-8. PubMed ID: 7496598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic modulation of KIT ligand in melanocytic disorders with implications for mast cell diseases.
    Sevilla A; Grichnik J
    Exp Dermatol; 2024 May; 33(5):e15091. PubMed ID: 38711220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting c-kit in the therapy of mast cell disorders: current update.
    El-Agamy DS
    Eur J Pharmacol; 2012 Sep; 690(1-3):1-3. PubMed ID: 22789565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional deregulation of KIT: link to mast cell proliferative diseases and other neoplasms.
    Cruse G; Metcalfe DD; Olivera A
    Immunol Allergy Clin North Am; 2014 May; 34(2):219-37. PubMed ID: 24745671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.
    Jensen BM; Akin C; Gilfillan AM
    Br J Pharmacol; 2008 Aug; 154(8):1572-82. PubMed ID: 18500355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.
    Bibi S; Arock M
    Immunol Allergy Clin North Am; 2018 Aug; 38(3):527-543. PubMed ID: 30007468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT as a master regulator of the mast cell lineage.
    Tsai M; Valent P; Galli SJ
    J Allergy Clin Immunol; 2022 Jun; 149(6):1845-1854. PubMed ID: 35469840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.
    Galli SJ; Tsai M; Wershil BK
    Am J Pathol; 1993 Apr; 142(4):965-74. PubMed ID: 7682764
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.